Probiotic-based Antiviral Systems and Therapies 2.0

A next-generation platform for predicting, preventing, and treating viral infections in mammals, leveraging advanced genomics, machine learning, CRISPR-Cas9 gene editing, and microfluidics to create personalized, targeted, and adaptive antiviral solutions.

The original patent disclosed the use of probiotic bacterial molecules for reducing the incidence and treatment of Rotavirus infections. However, this approach has limitations, such as the need for empirical identification of effective probiotic strains and the potential for variable efficacy. The new inventive concept addresses these limitations by integrating cutting-edge technologies to create a more proactive, precise, and effective antiviral system.

The new inventive concept comprises a system for predicting and preventing viral outbreaks, a method for creating personalized antiviral therapies, a composition combining live probiotic bacteria and synthetic antiviral molecules, a device for in-situ detection and elimination of viral pathogens, and a method for engineering probiotic bacteria to produce targeted antiviral molecules. These components work together to provide a comprehensive, adaptive, and effective solution for combating viral infections.

The new claims introduce several innovative elements, including the use of machine learning for identifying novel antiviral molecules, CRISPR-Cas9 gene editing for modifying probiotic bacteria, and microfluidics for in-situ detection and elimination of viral pathogens. These advancements significantly expand the capabilities and potential impact of the original patent, rendering the new inventive concept novel and non-obvious.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, gene editing tools, or microfluidic designs. Variations could involve applying the platform to different viral strains, incorporating additional diagnostic or therapeutic components, or integrating with existing healthcare systems.

The new inventive concept has significant commercial potential in the pharmaceutical, biotechnology, and healthcare industries. It could lead to the development of new antiviral therapies, diagnostic tools, and preventative measures, addressing a substantial unmet need in the market and improving public health outcomes.